Dietary Intake of Vitamins in Different Options of Treatment in Chronic Kidney Disease: Is There a Deficiency?

Magdalena Jankowska(Gdańsk Medical University), Sylwia Małgorzewicz(Gdańsk Medical University), Alicja Dębska‐Ślizień(Gdańsk Medical University), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Małgorzata Kaczkan(Gdańsk Medical University), N. Szupryczyńska(Gdańsk Medical University), Paulina Borek(Gdańsk Medical University)
Transplantation Proceedings
June 1, 2016
10.1016/j.transproceed.2015.11.039
Cited by 29

Related Papers

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2017|491